First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR ® and Oxtellar XR ® net sales (non-GAAP) ...

Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule ...

A pioneering clinical study found that pairing vagus nerve stimulation (VNS) with traditional therapy eliminated PTSD ...

Fremanezumab (Ajovy) reduced depression symptoms and monthly migraine attacks in people with episodic or chronic migraine and ...

In a first-of-its-kind clinical study, scientists at the University of Texas at Dallas and Baylor University Medical Center have shown that patients with treatment-resistant PTSD were symptom-free up ...

For parents and families supporting loved ones with depression, anxiety, or PTSD, this breakthrough represents a potential ...

Resveratrol, curcumin, and other plant compounds may counteract cellular pathways that lead to aging. Here's a list of ...

E veryone knows that red is hot and blue is cold – even blind people who have never seen colors. According to a new study, ...